Activity

The pancreatic parenchyma atrophy and dilatation of the main pancreatic duct had been gradually progressing. We performed distal pancreatectomy because of possibility of malignancy. The histopathological findings showed that 2 cystic tumors the side of pancreatic head had a connection and had typical findings of SCA of pancreas. The other tumor was independent from two tumors. They had no malignant findings.

At first, we expected tumor invasion had caused the changes. But tumors had no malignant findings, so we considered that compression from the tumor had caused stenosis, and obstructive pancreatitis had induced the pancreatic parenchyma atrophy.

We learned from this case that not only invasion but also compression caused vein stenosis and pancreatic duct dilation.

We learned from this case that not only invasion but also compression caused vein stenosis and pancreatic duct dilation.

Australia, although a high income economy, carries a significant burden of rheumatic heart disease (RHD). Acute rheumatic fever (ARF) and RHD are endemic in the Indigenous population. Immigrants from low/lower-income countries (‘non-Indigenous high-risk’) are also at increased risk compared with ‘non-Indigenous low-risk’ Australians. This study describes the utilisation of surgical and percutaneous procedures for RHD-related valve disease among patients aged less than 50 years, from 2002 to 2017.

A descriptive study using data from the ‘End RHD in Australia Study of Epidemiology (ERASE) Project’ linking RHD Registers and hospital inpatient data from five states/territories, and two surgical databases. Trends across three-year periods were determined and post-procedural all-cause 30-day mortality calculated.

A total of 3900 valves interventions were undertaken in 3028 procedural episodes among 2487 patients. Over 50% of patients were in the 35-49 years group, and 64% were female. Over 60% of procedures fncidence, and improve the early detection and management of ARF/RHD in high-risk populations within Australia.

The frequency of cardiac valve procedures, and 30-day mortality remained steady across 15 years. Some changes in the distribution of procedures in population groups were evident. Replacement procedures, the use of bioprosthetic valves, and multiple-valve interventions increased. The challenge for Australian public health officials is to reduce the incidence, and improve the early detection and management of ARF/RHD in high-risk populations within Australia.

Androgen deprivation therapy (ADT) has remained the first line strategy for treatment of advanced prostate cancers. Despite the profound efficacy of ADT in preventing clinical remission, 30-50% of advanced prostate cancer will develop resistance to hormonal deprivation therapy. This study aimed to evaluate the potential role of

and

expressions as biomarkers for predicting time to castration-resistant prostate cancer (CRPC).

The clinical and pathological data of patients with prostate cancer were collected retrospectively from Dr. selleck chemicals Sardjito General Hospital, Yogyakarta. Between 2015 and 2019, a total of 36 patients who received castration were included. Expressions of mRNA of

and

from primary tumors were quantified using quantitative Real Time Polymerase Chain Reaction (qRT-PCR).

The expressions of mRNA of

and

increased in prostate cancer tissues compared to hyperplastic prostates and significantly downregulated in metastatic prostate cancers (

<0.001). Lower mRNA

expression correlated with shorter time to CRPC among patients treated with ADT (

=0.006). In addition, stratified analysis showed that lower mRNA

expression was significantly associated with shorter CRPC both in metastatic (

=0.017) and non-metastatic (

=0.001) prostate cancer patients.

Low expression of mRNA of

and

3 has been shown to be a potential marker of shorter time to develop CRPC in patients with advanced stages of prostate cancer treated with ADT. Meanwhile, ISUP score >4 were not shown predictive value on time to CRPC.

4 were not shown predictive value on time to CRPC.

Composite graft as a reconstructive therapy option has limitations in size so that it is easily necrotic. Deferoxamine administration has been associated with increased neo-vascularity in wounds. We aimed to compare the administration of deferoxamine and Platelet-Rich Plasma (PRP) injection in a composite graft in rabbits.

Thirty New Zealand rabbits were divided into three groups; the control group, the deferoxamine group, and the PRP group. The composite graft with a diameter of 2cm was taken and replanted after rotating it 180°. The mean graft viability and the mean number of capillaries were evaluated on day 7 (POD 7) by macroscopic and histological evaluation using Hematoxylin-Eosin staining.

While the mean number of capillaries was not significantly different in control, deferoxamine, and PRP groups (

=0.21), the mean survival rate in the control, deferoxamine, and PRP groups reached a significant level with

-value of 0.006 (66.6%

63.8%

99.6%, respectively).

Deferoxamine group had the highest number of capillaries, but had the lowest survival rate. In the PRP group, it had the lowest number of capillaries, but had the highest survival rate.

Deferoxamine group had the highest number of capillaries, but had the lowest survival rate. In the PRP group, it had the lowest number of capillaries, but had the highest survival rate.Tuberculosis (TB) remains a major global public health problem. Hence, the study aimed to assess the impact of human immune virus (HIV) status and predictors of successful treatment outcomes of TB patients enrolled at Nekemte specialized hospital. An institution-based retrospective cohort study was conducted and the data analyzed using SPSS version 24.0. A multivariable logistic regression model was fitted to identify the association between treatment outcome and potential predictor variables. The association was calculated using the Adjusted Odds ratio (AOR) and the statistical significance was considered at p less then 0.05. Out of the total 506 study participants, 50.2% of them were males. The overall treatment success rate was 81.4% and 58.06% among HIV co-infected TB patients. Female sex (AOR = 2.01, 95%CI 1.04-16.11), age 25-34 years (AOR = 3.982, 95%CI 1.445-10.971), age 35-49 years (AOR = 5.392, 95%CI 1.674-17.368), high school educational level (AOR = 5.330, 95% CI 1.753-16.209), urban residence (AOR = 3.